Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging From Stealth Mode, Tesselate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs

Executive Summary

As investment and interest grows in synthetic lethality cancer treatments, Netherlands-headquartered Tesselate Bio hopes to expand horizons within the field by hitting the novel FANCM target and developing its own companion diagnostic.

You may also be interested in...



BMS Looks To Expand Its Oncology Reach With Mirati Buyout

Bristol Myers Squibb will add Krazati to its oncology portfolio by buying Mirati Therapeutics in a deal worth up to $5.8bn, but needs to smooth out the so-far bumpy progress of the KRAS-targeting agent and achieve success in immunotherapy combinations.

Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence

The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.

AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer

Early signs of improved safety and efficacy should set up PARP1 inhibitor for potential combinations and future broader use, but the true extent of its benefits remain to be seen.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel